P2RY12 and atrial fibrillation: Five studies have investigated strategies of early discontinuation or even only peri-procedural application of ASA in patients receiving a P2Y12 inhibitor with OAC: WOEST [49] dropped ASA on a VKA background, whereas PIONEER AF [16], RE-DUAL PCI [15], AUGUSTUS [17], and ENTRUST-AF PCI [18] evaluated dual strategies on the different NOAC backgrounds (Fig. 1, Table 2) [50, 51].